Skip to main content

vedolizumab (Entyvio®)

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria, vedolizumab (Entyvio®) can be made available within NHS Wales for the treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids and infliximab, or when infliximab is unsuitable.

The risks and benefits of the off-label use of vedolizumab (Entyvio®) for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision with decision rationale and start stop criteria Vedolizumab ICI enterocolitis. OW22. 2022 (PDF, 113Kb)
 Evidence Status Report. Vedolizumab for ICI enterocolitis. OW22. 2022 (PDF, 148Kb)

Medicine details

Medicine name vedolizumab (Entyvio®)
Formulation powder for solution for infusion
Reference number OW22
Indication

Treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids and/or other immunosuppressant drugs like infliximab, or when infliximab is unsuitable

Company Takeda UK Ltd
BNF chapter Gastro-intestinal system
Submission type One Wales
Status One Wales interim decision
Advice number OW22
Date of issue 02/02/2023
Follow AWTTC: